CD109

CD109 Molekülinformation

Englischer Name	DNA polymerase alpha subunit	Anzahl der inverkehr gebrachten Arzneimittel	2
Anzahl der klinischen Arzneimittel	3	Target-Alias	P180，N Syndrome (Mental Retardation， Malformations， Chromosome Breakage)，NSX，VEODS，Polymerase (DNA Directed)， Alpha，POLA1，Polymerase (DNA-Directed)， Alpha (70kD)，DNA Polymerase Alpha 1， Catalytic Subunit，POLA，EC:2.7.7.7，EC 2.7.7.7，DNA Polymerase Alpha Catalytic Subunit，DNA Polymerase Alpha Catalytic Subunit P180，Polymerase (DNA) Alpha 1， Catalytic Subunit，DNA Polymerase I，Polymerase (DNA Directed)， Alpha 1， Catalytic Subunit
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	DNA polymerase alpha subunit
Target-Alias	P180，N Syndrome (Mental Retardation， Malformations， Chromosome Breakage)，NSX，VEODS，Polymerase (DNA Directed)， Alpha，POLA1，Polymerase (DNA-Directed)， Alpha (70kD)，DNA Polymerase Alpha 1， Catalytic Subunit，POLA，EC:2.7.7.7，EC 2.7.7.7，DNA Polymerase Alpha Catalytic Subunit，DNA Polymerase Alpha Catalytic Subunit P180，Polymerase (DNA) Alpha 1， Catalytic Subunit，DNA Polymerase I，Polymerase (DNA Directed)， Alpha 1， Catalytic Subunit
Anzahl der inverkehr gebrachten Arzneimittel	2
Anzahl der klinischen Arzneimittel	3
Höchste Forschungs- und Entwicklungsphase	Approved

CD109 Produktliste

Attribut
Protein (4)
Produktbibliothek
Online (4)
Spezies
Human (3)Cynomolgus (1)
Etikett
His Tag & Avi Tag (1)His Tag (2)Fc Tag (1)
Marker
Biotin-labeled (1)Unconjugated (3)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
CD9-H5256	Human	HEK293	Human CD109 / CPAMD7 protein, Fc Tag	In den Warenkorb legen
CD9-H52H3	Human	HEK293	Human CD109 / CPAMD7 Protein, His Tag	In den Warenkorb legen
CD9-H82E4	Human	HEK293	Biotinylated Human CD109 / CPAMD7 Protein, His,Avitag™ (MALS & SPR verified)	In den Warenkorb legen
CD9-C52H5	Cynomolgus	HEK293	Cynomolgus CD109 / CPAMD7 Protein, His Tag	In den Warenkorb legen

Gesamtmenge4

CD109 Molekülhintergrund

CD109 is a glycosyl phosphatidylinositol (GPI)-linked glycoprotein that localizes to the surface of platelets, activated T-cells, and endothelial cells. CD109 is expressed in many malignant tumors, including various squamous cell carcinomas and adenocarcinomas, and plays a role as a multifunctional coreceptor.CD109 reportedly associates with transforming growth factor (TGF)-β receptors and negatively regulates TGF-β signaling in keratinocytes. Additionally, CD109 is potentially related to signal transducer and activator of transcription-3 signaling and aberrant cell proliferation.

CD109 Molekülalias

CD109,CPAMD7,r150,p180,CPAMD7

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Clofarabine (Boyen)	BY-101	Phase 3 Clinical	Boyen Therapeutics Inc	Leukemia, Myeloid, Acute	Details
Alkasar-18	NOAC; Alkasar-18; N4-octadecyl-ara-C	Phase 1 Clinical	University of Zurich	Cerebral Hemorrhage; Neoplasms; Atrial Fibrillation	Details
Sapacitabine	CS-682; CYC-682	Phase 1 Clinical	Daiichi Sankyo Co Ltd	Leukemia; Myelodysplastic Syndromes; Breast Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Carcinoma, Non-Small-Cell Lung	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Clofarabine	CAFdA; JC0707; GZ-393590; SAR-393590; 2-Cl-2-F-araA	Approved	Genzyme Corp	Clolar, Evoltra, Ivozall, Clofarex	United States	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Genzyme Corp	2004-12-28	Neoplasms; Angioimmunoblastic T-cell Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Waldenstrom Macroglobulinemia; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma; Lymphoproliferative Disorders; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Histiocytosis, Langerhans-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Multiple Myeloma; Leukemia; Lymphoma, Large B-Cell, Diffuse; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Leukemia, Lymphoid; Intestinal Neoplasms; Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Hematologic Neoplasms; Leukemia, Myeloid; Leukemia, Myelogenous, Chronic; Solid tumours	Details
Nelarabine	506U; 506-U78; GW-506U; GW-506U78; GI-262250X; NSC-686673	Approved	Novartis Pharma Ag, Glaxosmithkline Plc	Arranon, ArranonG, Atriance	United States	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma	Sandoz	2005-10-28	Sezary Syndrome; Mycosis Fungoides; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, T-Cell; Angioimmunoblastic T-cell Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, T-Cell, Cutaneous; Waldenstrom Macroglobulinemia; Lymphoma, T-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Multiple Myeloma; Leukemia-Lymphoma, Adult T-Cell; Myeloproliferative Disorders; Myelodysplastic Syndromes; Plasmacytoma; Lymphoma, B-Cell, Marginal Zone	Details